Illa, CT, Pegueroles, J, Claramunt-Molet, M, Pi-Cervera, A, Heras-Delgado, A, Gascón-Fontal, J, Idelsohn-Zielonka, S, Rico, M, Vidal, N, Martín-Aguilar, L, Caballero-Avila, M, Lleixà, C, Collet-Vidiella, R, Llarch, P, Llansó, L, Carbayo-Viejo, A, Vesperinas, A, Querol, L, Pascual-Goñi, E. Balance Assessment in Patients With Peripheral Neuropathies Using Digital Biomechanical Biomarkers. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).

Querol, L, Hourcade, S, Chow, T, Chen, Y, Levit, M, Hammond, TR, Kramer, ML, Ternes, N, Seluzhytsky, A, Alonso-Alonso, M, Atassi, N, Lewis, RA. Exploratory Biomarker Analyses in a Phase 2 Trial of Riliprubart for Chronic Inflammatory Demyelinating Polyneuropathy. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).

Allen, J, Lin, J, Stettner, M, Guptill, J, Istas, G, De Roeck, A, Kuwabara, S, Pinter, GL, Querol, L, Suresh, N, Karam, C, Skripuletz, T, Rinaldi, S, Echaniz-Laguna, A, Hewamadduma, C, Van Hoorick, B, Yamasaki, R, Van Doorn, PA, Lewis, RA. ADHERE plus Trial Interim Analysis: Long-Term Safety and Efficacy of Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).

Querol, L, Lewis, RA, Hartung, HP, van Doorn, PA, Lin, J, Dionne, A, Attarian, S, Wallstroem, E, Auwarter, K, Lu, Y, Alonso, MA, Atassi, N, Hughes, RAC. Safety and Efficacy of Riliprubart in CIDP: 76-Week Phase 2 Trial Results. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).